2020 Q1 Form 10-K Financial Statement
#000143774920005968 Filed on March 24, 2020
Income Statement
| Concept | 2020 Q1 | 2018 Q4 | 2018 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $460.0K | $330.0K | $2.110M |
| YoY Change | 53.33% | -71.79% | -38.3% |
| % of Gross Profit | |||
| Research & Development | $598.0K | $310.0K | $1.783M |
| YoY Change | 70.86% | -51.56% | -31.24% |
| % of Gross Profit | |||
| Depreciation & Amortization | |||
| YoY Change | |||
| % of Gross Profit | |||
| Operating Expenses | $598.0K | $640.0K | $1.783M |
| YoY Change | 70.86% | -64.64% | -31.24% |
| Operating Profit | -$1.066M | -$3.891M | |
| YoY Change | 63.25% | -35.32% | |
| Interest Expense | $4.000K | -$50.00K | $1.814M |
| YoY Change | -99.61% | -89.36% | 12.18% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$824.0K | -$140.0K | -$2.268M |
| YoY Change | -17.52% | -450.0% | -53.66% |
| Pretax Income | -$1.890M | -$830.0K | -$6.159M |
| YoY Change | 14.41% | -62.95% | -43.55% |
| Income Tax | -$92.00K | -$90.00K | -$254.0K |
| % Of Pretax Income | |||
| Net Earnings | -$1.798M | -$740.0K | -$5.905M |
| YoY Change | 13.73% | -65.74% | -43.08% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$268.3K | -$145.7K | -$1.268M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 6.631M | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2018 Q4 | 2018 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $1.300M | $1.410M | $1.410M |
| YoY Change | -5.8% | 840.0% | 840.0% |
| Cash & Equivalents | $1.296M | $1.405M | $1.410M |
| Short-Term Investments | |||
| Other Short-Term Assets | $390.0K | $110.0K | $110.0K |
| YoY Change | 457.14% | -45.0% | -45.0% |
| Inventory | |||
| Prepaid Expenses | $389.0K | $110.0K | |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $2.091M | $1.847M | $1.850M |
| YoY Change | 12.42% | 140.81% | 140.26% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | |||
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $45.00K | $51.00K | $50.00K |
| YoY Change | -11.76% | ||
| Total Long-Term Assets | $45.00K | $51.00K | $50.00K |
| YoY Change | -11.76% | ||
| TOTAL ASSETS | |||
| Total Short-Term Assets | $2.091M | $1.847M | $1.850M |
| Total Long-Term Assets | $45.00K | $51.00K | $50.00K |
| Total Assets | $2.136M | $1.898M | $1.900M |
| YoY Change | 11.77% | 147.46% | 146.75% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $271.0K | $1.064M | $1.060M |
| YoY Change | -70.06% | -11.04% | -11.67% |
| Accrued Expenses | $308.0K | $216.0K | $220.0K |
| YoY Change | 54.0% | -82.78% | -84.72% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $830.0K | $286.0K | $350.0K |
| YoY Change | 220.46% | 1942.86% | -77.27% |
| Total Short-Term Liabilities | $1.412M | $1.630M | $1.630M |
| YoY Change | -43.5% | -60.91% | -60.91% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $1.412M | $1.630M | $1.630M |
| Total Long-Term Liabilities | $0.00 | $0.00 | |
| Total Liabilities | $1.410M | $1.630M | $1.630M |
| YoY Change | -43.6% | -63.42% | -63.45% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$43.06M | -$35.06M | |
| YoY Change | 17.51% | 20.26% | |
| Common Stock | $7.000K | $5.000K | |
| YoY Change | 40.0% | 25.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $724.0K | $268.0K | $270.0K |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $2.136M | $1.898M | $1.900M |
| YoY Change | 11.77% | 147.46% | 146.75% |
Cashflow Statement
| Concept | 2020 Q1 | 2018 Q4 | 2018 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.798M | -$740.0K | -$5.905M |
| YoY Change | 13.73% | -65.74% | -43.08% |
| Depreciation, Depletion And Amortization | |||
| YoY Change | |||
| Cash From Operating Activities | -$1.120M | -$160.0K | -$2.387M |
| YoY Change | 43.04% | -79.75% | -29.84% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | |||
| YoY Change | |||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | $26.00K | $14.00K | |
| YoY Change | -3.7% | ||
| Cash From Financing Activities | -26.00K | 1.330M | 3.643M |
| YoY Change | -103.43% | 17.29% | |
| NET CHANGE | |||
| Cash From Operating Activities | -1.120M | -160.0K | -2.387M |
| Cash From Investing Activities | |||
| Cash From Financing Activities | -26.00K | 1.330M | 3.643M |
| Net Change In Cash | -1.153M | 1.170M | 1.256M |
| YoY Change | 4512.0% | -248.1% | -524.32% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.120M | -$160.0K | -$2.387M |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2019 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2019 | dei |
Security12g Title
Security12gTitle
|
Common Stock, $0.001 par value | |
| CY2019 | snbp |
Adjustments To Additional Paid In Capital Warrants Issued In Exchange For Modification Of Term Debt
AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInExchangeForModificationOfTermDebt
|
14000 | |
| CY2019Q4 | snbp |
Clinical Trial Related Liabilities Current
ClinicalTrialRelatedLiabilitiesCurrent
|
147000 | |
| CY2018Q4 | snbp |
Clinical Trial Related Liabilities Current
ClinicalTrialRelatedLiabilitiesCurrent
|
42000 | |
| CY2019 | snbp |
Common Stock Converted Into Convertible Notes Payable Value
CommonStockConvertedIntoConvertibleNotesPayableValue
|
25000 | |
| CY2018 | snbp |
Common Stock Converted Into Convertible Notes Payable Value
CommonStockConvertedIntoConvertibleNotesPayableValue
|
||
| CY2019 | snbp |
Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
|
||
| CY2018 | snbp |
Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
|
3258000 | |
| CY2019 | snbp |
Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock And Warrants
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants
|
2281000 | |
| CY2018 | snbp |
Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock And Warrants
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants
|
||
| CY2018Q2 | snbp |
Debt Instrument Convertible Gross Proceeds From Sale Of Equity Trigger
DebtInstrumentConvertibleGrossProceedsFromSaleOfEquityTrigger
|
2000000 | |
| CY2019Q4 | snbp |
Deferred Tax Liabilities Beneficial Conversion Feature Net
DeferredTaxLiabilitiesBeneficialConversionFeatureNet
|
||
| CY2018Q4 | snbp |
Deferred Tax Liabilities Beneficial Conversion Feature Net
DeferredTaxLiabilitiesBeneficialConversionFeatureNet
|
283000 | |
| CY2019 | snbp |
Effective Income Tax Rate Reconciliation Deferred True Up Percent
EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
|
0.163 | |
| CY2018 | snbp |
Effective Income Tax Rate Reconciliation Deferred True Up Percent
EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
|
||
| CY2019 | snbp |
Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent
EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent
|
0.057 | |
| CY2018 | snbp |
Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent
EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent
|
0.057 | |
| CY2019 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2019 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2019 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2019 | |
| CY2019 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2019-12-31 | |
| CY2019 | dei |
Document Type
DocumentType
|
10-K | |
| CY2019 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001029125 | |
| CY2020Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
6631308 | |
| CY2019 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2019 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2019 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2019Q2 | dei |
Entity Public Float
EntityPublicFloat
|
9495538 | |
| CY2019 | dei |
Entity Registrant Name
EntityRegistrantName
|
Sun BioPharma, Inc. | |
| CY2019 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2019 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2019 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2019 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2019 | dei |
Trading Symbol
TradingSymbol
|
snbp | |
| CY2019 | snbp |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.059 | |
| CY2018 | snbp |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
0.001 | |
| CY2018Q4 | snbp |
Grant Agreement Total Grants
GrantAgreementTotalGrants
|
225000 | |
| CY2019 | snbp |
Grant Income Nonoperating
GrantIncomeNonoperating
|
||
| CY2018 | snbp |
Grant Income Nonoperating
GrantIncomeNonoperating
|
54000 | |
| CY2019 | snbp |
Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
|
353000 | |
| CY2018 | snbp |
Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
|
716000 | |
| CY2019 | snbp |
Noncash Interest Expense
NoncashInterestExpense
|
102000 | |
| CY2018 | snbp |
Noncash Interest Expense
NoncashInterestExpense
|
4000 | |
| CY2018 | snbp |
Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
|
404000 | |
| CY2019 | snbp |
Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
|
733400 | |
| CY2018 | snbp |
Stock Issued During Period Value Conversion Of Convertible Securities Into Common Stock And Warrants
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesIntoCommonStockAndWarrants
|
3258000 | |
| CY2019 | snbp |
Stock Options Granted In Exchange For Release From Contingent Payment Obligations
StockOptionsGrantedInExchangeForReleaseFromContingentPaymentObligations
|
||
| CY2018 | snbp |
Stock Options Granted In Exchange For Release From Contingent Payment Obligations
StockOptionsGrantedInExchangeForReleaseFromContingentPaymentObligations
|
1094000 | |
| CY2019 | snbp |
Unsecured Promissory Note Issued In Exchange For Vendor Accounts Payable
UnsecuredPromissoryNoteIssuedInExchangeForVendorAccountsPayable
|
742000 | |
| CY2018 | snbp |
Unsecured Promissory Note Issued In Exchange For Vendor Accounts Payable
UnsecuredPromissoryNoteIssuedInExchangeForVendorAccountsPayable
|
||
| CY2019Q4 | snbp |
Unsecured Promissory Note Payable Current
UnsecuredPromissoryNotePayableCurrent
|
742000 | |
| CY2018Q4 | snbp |
Unsecured Promissory Note Payable Current
UnsecuredPromissoryNotePayableCurrent
|
||
| CY2019 | snbp |
Warrants Issued During Period Value Exchanged For Modification Of Debt
WarrantsIssuedDuringPeriodValueExchangedForModificationOfDebt
|
14000 | |
| CY2018 | snbp |
Warrants Issued During Period Value Exchanged For Modification Of Debt
WarrantsIssuedDuringPeriodValueExchangedForModificationOfDebt
|
||
| CY2019Q4 | snbp |
Working Capital
WorkingCapital
|
1300000 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
597000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1064000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
304000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
216000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
125000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
157000 | |
| CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
305000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
283000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
42331000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
35038000 | |
| CY2019 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
2066000 | |
| CY2018 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
1732000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
716000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
353000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2373000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1093000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
419000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
739000 | |
| CY2019 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
12000 | |
| CY2018 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
9000 | |
| CY2019 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5166910 | |
| CY2018 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3451355 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
3144000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
1898000 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
3093000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1847000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2449000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1405000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
152000 | |
| CY2019 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1044000 | |
| CY2018 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1253000 | |
| CY2019Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3422099 | |
| CY2019Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
5186459 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
6631308 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
5077483 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
6631308 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
5077483 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
7000 | |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
5000 | |
| CY2019 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-6178000 | |
| CY2018 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-5457000 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.006 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
|
0.01 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
|
0.009 | |
| CY2019 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">redit </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">isk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses on its deposits of cash.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2019Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
||
| CY2018Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
64000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
7844000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
6084000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
||
| CY2018Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
283000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
6307000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
4807000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
72000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
71000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
235000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
235000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1230000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
971000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
7844000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
5801000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
||
| CY2018Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
283000 | |
| CY2019 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.09 | |
| CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.27 | |
| CY2019 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-1000 | |
| CY2018 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-3000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.057 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.057 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.324 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.226 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
||
| CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1973000 | |
| CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2108000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-6615000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-6159000 | |
| CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-415000 | |
| CY2018 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-254000 | |
| CY2019Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
361000 | |
| CY2018Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
332000 | |
| CY2019 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
301000 | |
| CY2018 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
360000 | |
| CY2019 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
92000 | |
| CY2018 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
59000 | |
| CY2019 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
31000 | |
| CY2018 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
-50000 | |
| CY2019 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
174000 | |
| CY2018 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-25000 | |
| CY2019 | us-gaap |
Interest Expense
InterestExpense
|
2194000 | |
| CY2018 | us-gaap |
Interest Expense
InterestExpense
|
1814000 | |
| CY2019 | us-gaap |
Interest Paid Net
InterestPaidNet
|
14000 | |
| CY2018 | us-gaap |
Interest Paid Net
InterestPaidNet
|
67000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
1759000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
1630000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
3144000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1898000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1759000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1630000 | |
| CY2019 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Risks and Uncertainties</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years, and is normally expected to involve substantial expenditures.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have incurred losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$41.3</div> million since our inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>we incurred a net loss and negative cash flows from operating activities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.7</div> million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and the clinical development of our primary product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>we had cash of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.4</div> million, working capital of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million and stockholders’ equity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million. The Company’s principal sources of cash have included the issuance of convertible debt and equity securities.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101,</div> in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern.</div></div> | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3784000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3643000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2739000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2387000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-41300000 | ||
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6200000 | |
| CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5905000 | |
| CY2018 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
||
| CY2019 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2349000 | |
| CY2018 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1783000 | |
| CY2019 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2293000 | |
| CY2018 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2268000 | |
| CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4322000 | |
| CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3891000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
32000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
17000 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
51000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
51000 | |
| CY2019 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
22000 | |
| CY2018 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
448000 | |
| CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-99000 | |
| CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-508000 | |
| CY2019 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
7000 | |
| CY2018 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
5000 | |
| CY2019 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
16000 | |
| CY2018 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
27000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2019Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
283000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
110000 | |
| CY2019 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
810000 | |
| CY2018 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
1329000 | |
| CY2019 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
3160000 | |
| CY2018 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
2328000 | |
| CY2019 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
161000 | |
| CY2018 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
14000 | |
| CY2019 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
25000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-41258000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-35058000 | |
| CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1093000 | |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1279000 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.72 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.72 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
19549 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1060400 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
732149 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
75749 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
20800 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
404000 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
733400 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.09 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
169495 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
56225 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1030547 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
733960 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1032211 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1744811 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.79 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.90 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.53 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
7.34 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
15.10 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
7.49 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.42 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
1346936 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
1744811 | |
| CY2018Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
42500 | |
| CY2019Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
397875 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
||
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
|
||
| CY2018Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
4.83 | |
| CY2019Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
2.03 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
378025 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
2.41 | |
| CY2019 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
|
P7Y69D | |
| CY2019Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
6.526 | |
| CY2019 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P7Y244D | |
| CY2019 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
2281000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2328000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
3160000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1385000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
268000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3689000 | |
| CY2019Q4 | us-gaap |
Unsecured Debt Current
UnsecuredDebtCurrent
|
116000 | |
| CY2018Q4 | us-gaap |
Unsecured Debt Current
UnsecuredDebtCurrent
|
286000 | |
| CY2019 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2019 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
5700314 | |
| CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
4662080 |
